Zydus Cadila India has sought regulatory approval for human trials of its Covid-19 antibody cocktail for the treatment of mild Covid-19 infections, as the country is dealing with the shortage of medicines and vaccines required to fight the second wave of Covid-19 pandemic.
The candidate, ZRC-3308, has depicted significant results in decreasing the lung damage amid animal trials revealed Zydus Cadila, further adding that it has proven to be safe and well-tolerated.
The therapy comprises a blended cocktail with two monoclonal antibodies which mimic natural antibodies produced by the body as an immune response to fight infections.
In a stock filing, Zydus Cadila’s managing director, Sharvil Patel said, “At this juncture, there is a critical need to explore safer and more efficacious treatments to combat COVID.”
The company has applied to get permission for conducting early-late stage human clinical trials from the Drugs Controller General of India (DCGI), revealed Zydus.
The US and Food Drugs Administration has given the emergency use authorization for such treatments advanced by Vir Biotechnology and GlaxoSmithKline along with the ones developed by Regeneron Pharmaceuticals and Eli Lilly.
The DCGI has also given approval for the antibody cocktail by Regeneron and Roche, and the developed treatment will be supplied in the country by the distributor Cipla. The very first batch of the cocktail was introduced in India in the beginning of the week.
